OBJECTIVETo evaluate the effectiveness of the restoration of aphasic disorders in patients in the early recovery period of ischemic stroke (IS) who received complex therapy, which included speech therapy and injections of the drug Cellex.MATERIAL AND METHODSThe study included 62 right-handed patients with aphasia hospitalized in the acute period of IS in Ramenskoye Hospital, who subsequently underwent the second stage of rehabilitation in the neurological department of the Moscow regional clinical institute n.a. M.F. Vladimirskiy. Patients received rehabilitation treatment at both stages, including speech therapy sessions, and were randomized into two groups. Group 1 - 32 patients, whose treatment complex included two courses of injections of Cellex in the acute and recovery period (main group), patients of group 2 (n=30) received basic and therapy for secondary prevention of IS. To assess the condition of patients, the stroke scale of the National Institutes of Health of the United States (NIHSS), a modified Rankin scale, a screening method for patients with aphasia, and the Goodglass-Kaplan scale (GKS) were used.RESULTSThere was a statistically significant improvement in the neurological status in patients of both groups in both the acute and early recovery periods, and the shifts in patients of group 1 in both periods of IS were higher. After the course of treatment, a statistically significant regression of aphasia was noted: in patients of group 1, the score increased from 1 [0.75, 2] to 4 [3, 4] points, whereas in patients of group 2 - from [0, 1.75] to 3 [2, 3.75] points (p<0.001 between groups). Communication skills in group 1 patients increased from 0.5 [0, 1] to 4 [2, 4] points, while in group 2 patients - from 1 [0, 2] to 3 [1, 3] points (p<0.001 between groups).CONCLUSIONAs a result of the study, data were obtained indicating that drug support for rehabilitation measures with Cellex, carried out in the form of two consecutive courses in the acute and early recovery periods of IS, significantly increased the effectiveness of speech therapy and accelerated the consolidation of the speech network of the brain, obviously because of activation of neuroplasticity processes.

2023-01-01·Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova

Results of evaluation of the effectiveness of the drug Cellex in patients with small vessel disease

Article

作者: Chipova, D T ; Malashenkov, N D ; Kamchatnov, P R ; Khanmurzaeva, S B ; Mityaeva, E V ; Abusueva, B A

OBJECTIVETo study the effect of the drug Cellex on the severity of cognitive impairment in patients with small vessel disease (SVD).MATERIAL AND METHODSA non-interventional observational controlled prospective observational study in parallel groups was conducted. 118 patients with CHEM who received unified therapy were under observation. Group 1 consisted of 40 patients who, in addition to basic therapy, received 10 injections of Cellex subcutaneously (0.2 ml 1 time/day), group 2 - 39 patients who received 2 courses of injections of Cellex subcutaneously (0.1 ml 1 time/day) with an interval of one month, patients 3-both groups (n=39) received only basic therapy. The examination included an assessment of the clinical status and neuropsychological testing (the MOS questionnaire and the clock drawing test - TRCH), analysis of the results of MRI of the brain. The blood levels of homocysteine (HC), C-reactive protein (CRP), asymmetric dimethylarginin (ADMA), and von Willebrand factor (FW) were determined in dynamics.RESULTSA statistically significant improvement in the performance of the MoCA and TRP questionnaire tests in groups 1 and 2 was demonstrated, with a more pronounced and persistent effect in patients who received repeated courses of treatment. Clinical improvement was accompanied by normalization of the concentration of studied markers of inflammation (CRP) and endothelial dysfunction (HC, ADMA, FW) in the blood, while the dynamics was most pronounced in patients of group 2. The treatment was characterized by good tolerability, low frequency and insignificant severity of adverse events.CONCLUSIONThe drug Cellex has demonstrated significant effectiveness in the treatment of patients with SVD with cognitive impairment, against the background of treatment, there was a decrease in markers of inflammation and endothelial dysfunction, therapy was characterized by good tolerability.

2023-01-01·Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

Effektivnost' i bezopasnost' primeneniya preparata Tselleks dlya lecheniya patsientov s kognitivnymi narusheniyami s khronicheskoi ishemiei golovnogo mozga — rezul'taty mnogotsentrovogo randomizirovannogo dvoinogo slepogo platsebo-kontroliruemogo klinicheskogo issledovaniya.

Article

作者: Fidler, M S ; Chubykin, V I ; Koltsov, I A ; Shchukin, I A

OBJECTIVETo evaluate the efficacy and safety of using Cellex for the treatment of cognitive impairment as part of the complex therapy of patients with chronic cerebral ischemia (CCI) compared with placebo.MATERIAL AND METHODSThe study randomized 300 patients with a reliable diagnosis of CCI stage 1-2, all participants were divided into two groups, 150 participants in each - main and control. The study drug Cellex or placebo was administered as two 10-day treatment courses, 1 ml once a day. The duration of the study was 90±5 days for each participant. The primary end point for evaluating the effectiveness of the therapy was the degree of improvement in the state of cognitive functions relative to the initial state according to the Montreal Cognitive Dysfunction Scale (MoCA) on the 31st and 60th days from the start of therapy in the compared groups. Secondary endpoints were the assessment of the degree of improvement in the state of cognitive functions according to psychometric testing scales (MoCA, Correction Test, Frontal Dysfunction Test Battery) relative to the initial state on the 31^st, 60^th and 90^th days from the start of therapy. Also, a dynamic assessment of the systemic concentration of markers of brain damage - S100β, GFAP, MMP9 and neurotrophins - BDNF and GDNF was carried out.RESULTSThe primary endpoint of the study was achieved-the MoCA score in each group increased uniformly after baseline. However, in the main group, this indicator was significantly higher starting from visit 3 - 23.4±2.8 points in the main group, in the placebo group 22.7±2.3 (p<0.001), a statistically significant difference also remained at visit 5 (p<0.001). When analyzing the secondary endpoints according to the battery of frontal dysfunction tests and the correction test, a more pronounced positive trend was also noted in the main group. Changes in the emotional sphere in both groups remained within the normal range. The dynamics of the systemic concentration of markers of brain damage and neurotrophins was multidirectional, the assessment of which was possible only at the trend level.CONCLUSIONBased on the statistical analysis of the results of the study, Cellex was confirmed to be superior to Placebo in the degree of improvement in cognitive functions measured by the MoCA scale after the 1st and 2nd treatment courses.

100 项与 Cellex 相关的药物交易

登录后查看更多信息